Show simple item record

dc.contributor.authorSnipstad, Sofie
dc.contributor.authorSulheim, Einar
dc.contributor.authorDavies, Catharina de Lange
dc.contributor.authorMoonen, Chrit
dc.contributor.authorStorm, Gert
dc.contributor.authorKiessling, Fabian
dc.contributor.authorSchmid, Ruth
dc.contributor.authorLammers, Twan
dc.date.accessioned2019-04-01T13:36:58Z
dc.date.available2019-04-01T13:36:58Z
dc.date.created2019-01-02T13:59:58Z
dc.date.issued2018
dc.identifier.citationExpert Opinion on Drug Delivery. 2018, 15 (12), 1249-1261.nb_NO
dc.identifier.issn1742-5247
dc.identifier.urihttp://hdl.handle.net/11250/2592747
dc.description.abstractIntroduction: Ultrasound in combination with microbubbles can make cells and tissues more accessible for drugs, thereby achieving improved therapeutic outcomes. In this review, we introduce the term ‘sonopermeation’, covering mechanisms such as pore formation (traditional sonoporation), as well as the opening of intercellular junctions, stimulated endocytosis/transcytosis, improved blood vessel perfusion and changes in the (tumor) microenvironment. Sonopermeation has gained a lot of interest in recent years, especially for delivering drugs through the otherwise impermeable blood-brain barrier, but also to tumors. Areas covered: In this review, we summarize various in vitro assays and in vivo setups that have been employed to unravel the fundamental mechanisms involved in ultrasound-enhanced drug delivery, as well as clinical trials that are ongoing in patients with brain, pancreatic, liver and breast cancer. We summarize the basic principles of sonopermeation, describe recent findings obtained in (pre-) clinical trials, and discuss future directions. Expert Opinion: We suggest that an improved mechanistic understanding, and microbubbles and ultrasound equipment specialized for drug delivery (and not for imaging) are key aspects to create more effective treatment regimens by sonopermeation. Real-time feedback and tools to predict therapeutic outcome and which tumors/patients will benefit from sonopermeation-based interventions will be important to promote clinical translation.nb_NO
dc.language.isoengnb_NO
dc.publisherTaylor & Francisnb_NO
dc.relation.urihttps://www.tandfonline.com/doi/full/10.1080/17425247.2018.1547279
dc.titleSonopermeation to improve drug delivery to tumors: from fundamental understanding to clinical translationnb_NO
dc.typeJournal articlenb_NO
dc.typePeer reviewednb_NO
dc.description.versionacceptedVersionnb_NO
dc.source.pagenumber1249-1261nb_NO
dc.source.volume15nb_NO
dc.source.journalExpert Opinion on Drug Deliverynb_NO
dc.source.issue12nb_NO
dc.identifier.doi10.1080/17425247.2018.1547279
dc.identifier.cristin1648689
dc.relation.projectSamarbeidsorganet mellom Helse Midt-Norge og NTNU:nb_NO
dc.description.localcodeLocked until 19.11.2019 due to copyright restrictions. This is an [Accepted Manuscript] of an article published by Taylor & Francis in [Expert Opinion on Drug Delivery] on [19 Nov 2018], available at https://doi.org/10.1080/17425247.2018.1547279nb_NO
cristin.unitcode194,66,20,0
cristin.unitnameInstitutt for fysikk
cristin.ispublishedtrue
cristin.fulltextpreprint
cristin.qualitycode1


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record